Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.

Laureate To Manufacture Tolera's Monoclonal Antibody Product

31-Oct-2008 - Laureate Pharma, Inc. announced that it has entered into a cGMP contract manufacturing agreement with Tolera Therapeutics, Inc.. According to the agreement, Laureate will produce Tolera's TOL101 monoclonal antibody under cGMP conditions to be used in clinical trials. Terms of the manufacturing ...

Laureate Pharma to Add More Manufacturing Capacity

Laureate To Add Single-Use Bioreactor (S.U.B.) To Its Portfolio Of

22-Sep-2008 - Laureate Pharma, Inc. announced that it is increasing its existing manufacturing capacity by adding two Single-Use Bioreactors (S.U.B.). Acquisition of a 250L and a 1000L S.U.B. will give Laureate greater flexibility in meeting the varying needs of its clients. The S.U.B. is a single-use ...

Laureate Pharma opens pilot plant in Princeton, NJ

Facility Will Develop, Produce and Purify Early-Phase Pre-Clinical Proteins

30-Mar-2007 - Laureate Pharma announced that it has formally opened its newly constructed Pilot Plant in Princeton, NJ for pre-clinical biopharmaceutical manufacturing. The plant is now available for early engineering runs and production of product for uses such as formulation and toxicological testing. The ...

Laureate Pharma announces collaboration with Boehringer Ingelheim

08-Feb-2007 - Laureate Pharma, Inc. announced a preferred partnership agreement with Boehringer Ingelheim. With this collaboration, Laureate's clients will gain access to Boehringer Ingelheim's comprehensive manufacturing technology platform for biopharmaceutical products produced by mammalian cell ...